Atena Pourtaji, Vajiheh Jahani, Amirhossein Sahebkar*, Thozhukat Sathyapalan and Amir Hooshang Mohammadpour* Pages 2080 - 2089 ( 10 )
Heart Failure (HF) is recognized as an important public health concern worldwide, especially in developed countries, due to its high rate of morbidity and mortality. Although new pharmacological and non-pharmacological agents have improved the clinical sequelae of HF in patients, its mortality remains high, especially among the elderly. Erythropoietin (EPO), a glycoprotein, besides its traditional role in promoting erythropoiesis and production of erythroid progenitors, its beneficial role in reducing infarct area and improving heart function through EPO-induced antiapoptotic and antioxidant effects have been increasingly recognized. This review gathers the evidence to date about the effectiveness of EPO in HF patients. In addition to the growing evidence of EPO in the treatment of HF in the animal studies for improving cardiac function and infarct size, more clinical studies are needed to assess the role of EPO treatment in the management of HF.
Congestive heart failure, erythropoietin, clinical trial, endothelial precursor cell, ROS, AMPK.
Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Halal Research Center of IRI, FDA, Tehran, Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, Department of Clinical Pharmacy, Mashhad University of Medical Sciences, Mashhad